Elevance Health profit margin ELV
Gross, operating and net profit as a share of revenue over the last twelve months, from 2009.
- Net margin, 12 months
- 2.5%
- Net margin on a year earlier
- −0.4 pts
- Peer median
- 1.7%
Over the twelve months to Jun 30, 2026, Elevance Health kept 2.5% of its revenue as net profit and a gross margin of 89.1%.
Five years earlier its net margin was 3.3%.
The median for 6 health insurers of a similar size is 1.7%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Gross margin |
|---|---|---|
| FY2025 | 2.8% | 89.4% |
| FY2024 | 3.4% | 88.8% |
| FY2023 | 3.5% | 89.9% |
| FY2022 | 3.8% | 91.7% |
| FY2021 | 4.4% | 92.1% |
| FY2020 | 3.8% | 92.7% |
| FY2019 | 4.6% | 98.1% |
| FY2018 | 4.1% | n/a |
| FY2017 | 4.3% | n/a |
| FY2016 | 2.9% | n/a |
| FY2015 | 3.2% | n/a |
| FY2014 | 3.5% | n/a |
| FY2013 | 3.5% | n/a |
| FY2012 | 4.3% | n/a |
| FY2011 | 4.4% | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year |
|---|---|---|---|
| Q2 FY26 | 2.5% | −0.4 pts | |
| Q1 FY26 | 2.6% | −0.6 pts | |
| Q4 FY25 | 2.8% | −0.5 pts | |
| Q3 FY25 | 2.8% | −0.8 pts | |
| Q2 FY25 | 2.8% | −1.1 pts | |
| Q1 FY25 | 3.2% | −0.4 pts | |
| Q4 FY24 | 3.4% | −0.1 pts | |
| Q3 FY24 | 3.7% | +0.1 pts | |
| Q2 FY24 | 3.9% | +0.1 pts | |
| Q1 FY24 | 3.6% | −0.2 pts | |
| Q4 FY23 | 3.5% | −0.3 pts | |
| Q3 FY23 | 3.6% | −0.5 pts |
Against its peers
Companies in Medical - Healthcare Plans nearest Elevance Health's size, closest first, today.
| Company | Profit margin |
|---|---|
| ELVElevance Health | 2.5% |
| CICigna | 2.3% |
| CVSCVS Health | 1.2% |
| HUMHumana | 0.9% |
| CNCCentene | −2.5% |
| UNHUnitedHealth | 3.5% |
| OSCROscar Health | 3.6% |
| Peer median | 1.7% |
Where Elevance Health ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Elevance Health
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.